Supplementary Figure S3.

EASI-75 was estimated from percentage-improved EASI using a regression curve. The regression curve was obtained using the reported percentage-improved EASI and EASI-75 in clinical trials of multiple treatments (all available time points of both drug- and placebo-treated groups in dupilumab [Blauvelt et al., 2017], nemolizumab [Kabashima et al., 2020], tezepelumab [Simpson et al., 2019], GBR 830 [Guttman-Yassky et al., 2019b], lebrikizumab [Guttman-Yassky et al., 2020], and tralokinumab [Silverberg et al., 2021]). EASI, Eczema Area and Severity Index; Ph, phase.